Accordingly, PSF algorithms only showed higher SUVmax than non-PSF algorithms in lesions with a high TBR (median differences at low/high TBR, +2.6%/+9.1% [PSF + TOF vs. 3D-OSEM + TOF]; +0.7%/+6.4% [PSF vs. 3D-OSEM]).
*Cells not sharing the same subscript indicate significantly median differences at 5% significance level in a two-sided Kruskal-Wallis test for the equality of the medians of working hours among Private, Public, and Dual practitioners.
To detect a median difference of at least 10° between the resulting mismatch distributions under assumption of a difference standard deviation of 20°, the effective sample size of 80 patients ensures a statistical power of 99%, when a two-sided paired t-test were applied at the 5% significance level.
In the NHANES sample, the median difference between age at breast cancer diagnosis and age at UCd measurement was 7 years, and ranged from 5-12 years in the LIDPBC sample.
The primary end point was median difference in 6MWD at 16 weeks, which was not statistically different between groups (+11 m, 95% CI: 0.0 22 m, P=0.07).
The primary outcome of this study was placebo-corrected Hodges Lehmann between-treatment median difference in 6MWD at 16 weeks.
The primary outcome was placebo-corrected Hodges Lehmann between-treatment median difference in 6MWD at 12 weeks.
The median difference between LAPAQ at T = 1 and the ACTR LAPAQQ minus ACTR) was –510 minutes and the PCC was 0.25 (95% CI 0.07 0.44).
The difference between evaluations ranged between -10 to +12 points, with a median difference of 0. At the time of last neuropsychological evaluation 6 patients had a cerebellar syndrome.
Using a modified intention-to-treat analysis that included only patients who had access to 0.25 mg tablets at randomization (n=228), the FREEDOM-M trial demonstrated a statistically significant increase in the median difference in 6MWD at 12 weeks relative to placebo (+23 m, 95% CI: 4 41 m, P=0.0307).
